VERONICA ZAVALA-CARRAWAY: Open Payments
NPI 1184998197 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$715 in 36 payments from 8 companies in 2025. Trend: 2023 $331 · 2024 $64 · 2025 $715
Food & beverage: $715
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $233 |
| Novo Nordisk Inc | 8 | $163 |
| Lilly USA, LLC | 11 | $149 |
| Amgen Inc. | 4 | $68 |
| Merck Sharp & Dohme LLC | 2 | $39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: FARXIGA, Rybelsus, MOUNJARO, OTEZLA, AIRSUPRA, Ozempic, LAGEVRIO, JARDIANCE.
Industry payments across TX — which companies pay providers there.
